TY - JOUR
T1 - Search for therapeutic agents for cardiac arrest using a drug discovery tool and large-scale medical information database
AU - Zamami, Yoshito
AU - Niimura, Takahiro
AU - Koyama, Toshihiro
AU - Shigemi, Yuta
AU - Izawa-Ishizawa, Yuki
AU - Morita, Mizuki
AU - Ohshima, Ayako
AU - Harada, Keisaku
AU - Imai, Toru
AU - Hagiwara, Hiromi
AU - Okada, Naoto
AU - Goda, Mitsuhiro
AU - Takechi, Kenshi
AU - Chuma, Masayuki
AU - Kondo, Yutaka
AU - Tsuchiya, Koichiro
AU - Hinotsu, shiro
AU - Kano, Mitsunobu R.
AU - Ishizawa, Keisuke
N1 - Funding Information:
This research was supported by the Japan Research Foundation for Clinical Pharmacology Grant (grant number 2018A10) and the Japan Society for the Promotion of Science (JSPS) KAKENHI (grant number 18K06785).
Funding Information:
This study was conducted in keeping with the Ministry of Health, Labour, and Welfare’s Ethical Guidelines for Epidemiological Research. It was approved by the Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences and Okayama University Hospital Ethics Committee (No. 1706-022-001) and conformed to the tenets of the Declaration of Helsinki. Since this study was an observational study with anonymized information, with no treatment intervention and no collection of human samples, obtainment of informed consent was exempted.
Publisher Copyright:
Copyright © 2019 Zamami, Niimura, Koyama, Shigemi, Izawa-Ishizawa, Morita, Ohshima, Harada, Imai, Hagiwara, Okada, Goda, Takechi, Chuma, Kondo, Tsuchiya, Hinotsu, Kano and Ishizawa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
PY - 2019
Y1 - 2019
N2 - The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using “TargetMine,” a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to ≥10 patients and the objective variable being the “survival discharge.” Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to ≥10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients.
AB - The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using “TargetMine,” a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to ≥10 patients and the objective variable being the “survival discharge.” Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to ≥10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients.
KW - Cardiac arrest
KW - Claims database
KW - Drug discovery tool
KW - Drug repositioning
KW - Vasodilator
UR - http://www.scopus.com/inward/record.url?scp=85075592155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075592155&partnerID=8YFLogxK
U2 - 10.3389/fphar.2019.01257
DO - 10.3389/fphar.2019.01257
M3 - Article
AN - SCOPUS:85075592155
SN - 1663-9812
VL - 10
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1257
ER -